Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults
The CDC Clinician Outreach and Communication Activity (COCA)* presents…Clinical Considerations: Myocarditis and Pericarditis after Receipt of mRNA COVID-19 Vaccines Among Adolescents and Young Adults
Since April 2021, increased cases of myocarditis and pericarditis have been reported in the United States after mRNA COVID-19 vaccination (Pfizer-BioNTech and Moderna). The Centers for Disease Control and Prevention (CDC) is aware of these reports, which are rare given the number of vaccine doses administered.
CDC published clinical considerations for myocarditis and pericarditis following COVID-19 vaccination. In addition, resources for the public have been added to CDC’s website that can be a resource for your patients. CDC and its partners are actively monitoring these reports by reviewing data and medical records to learn more about what happened and to see if there is any relationship to COVID-19 vaccination. Please report all cases of myocarditis and pericarditis post COVID-19 vaccination to the Vaccine Adverse Event Reporting System (VAERS).
CDC continues to recommend COVID-19 vaccination for everyone 12 years of age and older, given the greater risk of COVID-19 illness and related, possibly severe complications.
Questions? Contact the Centers for Disease Control & Prevention: 1-800-CDC-INFO (800-232-4636) TTY: 888-232-6348
* NOTE: This is an industry resource and/or supplier-sponsored publication. HealthTrust has not approved and/or endorsed the content. This program may contain the mention of products, services, drugs or brands presented in a case study or comparative format. Such examples are intended for educational and informational purposes and should not be perceived as a HealthTrust endorsement of any particular supplier, product, service, drug, brand or approach.